EHA 2022 | The SHINE trial: controversies and unanswered questions
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil , Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the Phase III SHINE (NCT01776840) data that was released at this year’s EHA congress. The SHINE study investigates the addition of ibrutinib to bendamustine-rituximab (BR) and rituximab (R) maintenance in the frontline treatment of older patients with mantle cell lymphoma (MCL). While the trial reported a benefit in progression-free survival (PFS) for patients treated with ibrutinib, there was no advantage in overall survival (OS), which has created a debate around the benefit of using ibrutinib upfront. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria: Roche, Takeda, Gilead, Pfizer, MSD, Celleron, ADC Therapeutics, Incyte, Beigene. Research funding: BMS, MSD, Celleron, Amgen, BMS
